Apnimed, Inc. (NASDAQ:APMD – Get Free Report)’s stock price rose 6.2% during mid-day trading on Tuesday. The company traded as high as $17.32 and last traded at $17.29. 141,006 shares traded hands during trading, a decline of 69% from the average session volume of 449,775 shares. The stock had previously closed at $16.28.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on APMD shares. Weiss Ratings assumed coverage on Apnimed in a report on Tuesday, October 27th. They set a “sell (e-)” rating on the stock. Evercore assumed coverage on Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating on the stock. Lifesci Capital started coverage on Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating and a $50.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Apnimed in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. Finally, Bank of America started coverage on shares of Apnimed in a research report on Tuesday, August 25th. They issued a “buy” rating and a $41.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.33.
View Our Latest Report on APMD
Apnimed Trading Up 6.4%
The firm has a market cap of $721.45 million and a P/E ratio of 6.59. The company has a 50-day simple moving average of $20.29.
Apnimed (NASDAQ:APMD – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($1.05) EPS for the quarter. The company had revenue of $2.48 million during the quarter. Equities research analysts forecast that Apnimed, Inc. will post -0.24 earnings per share for the current fiscal year.
Institutional Trading of Apnimed
A hedge fund recently bought a new stake in Apnimed stock. Integral Health Asset Management LLC acquired a new position in Apnimed, Inc. (NASDAQ:APMD – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 225,000 shares of the company’s stock, valued at approximately $4,930,000. Integral Health Asset Management LLC owned about 0.54% of Apnimed at the end of the most recent quarter.
Apnimed Company Profile
Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.
Read More
- Five stocks we like better than Apnimed
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
